The second ASO drug, Mipomersen was for homozygous familial hypercholesterolemia (HoFH), which forms a double-strand complex with apolipoprotein B (APOB) transcript and causes its degradation through ribonuclease RNase H [27]. The gene discussed is APOB; the disease is homozygous familial hypercholesterolemia.